GSK press releases
Follow
Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
If approved, depemokimab will be the first and only ultra-long-acting biologic in the EU to treat respiratory diseases.
